Retroviral vector production in the National Gene Vector Laboratory at Indiana University

K. Cornetta, L. Matheson, C. Ballas

Research output: Contribution to journalArticle

15 Scopus citations


The National Gene Vector Laboratory (NGVL) is a US National Institutes of Health initiative charged with providing clinical grade vectors for gene therapy trials. The program was started in 1995 and Indiana University has served as the production site for retroviral vectors and is also accepting applications for production of lentiviral vectors. The facility is designed to produce vectors for Phase I and Phase II clinical trials with the specific mandate to facilitate investigator-initiated research for academic institutions. To date, the facility has generated over 30 Master Cell Banks for gene therapy investigators throughout the United States. This required the facility to develop a system that can adapt to the varied needs of investigators, most of whom request different vector backbones, packaging cell lines, final product volumes, and media. In this review, we will illustrate some of the experiences of the Indiana University NGVL during the generation of retroviral vectors using murine-based packaging cell lines.

Original languageEnglish (US)
Pages (from-to)S28-S35
JournalGene Therapy
StatePublished - Oct 2005


  • Replication-competent retrovirus
  • Retroviral gene transfer
  • Vector production

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'Retroviral vector production in the National Gene Vector Laboratory at Indiana University'. Together they form a unique fingerprint.

  • Cite this